Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #15 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| IPCA Laboratories Limited (this stock) | 48,889 | 39.3 | 12.4% | 45.2% | — | 79 | 9 | 49 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 2,788 | 572 | 424 | ₹ |
| March 31, 2026 | 2,388 | 404 | 307 | ₹ |
| Dec. 31, 2025 | 2,392 | 446 | 364 | ₹ |
| Sept. 30, 2025 | 2,556 | 392 | 281 | ₹ |
| June 30, 2025 | 2,309 | 331 | 233 | ₹ |
| March 31, 2025 | 2,247 | 128 | 64 | ₹ |
| Dec. 31, 2024 | 2,245 | 368 | 276 | ₹ |
| Sept. 30, 2024 | 2,355 | 345 | 246 | ₹ |
| June 30, 2024 | 2,093 | 290 | 199 | ₹ |
| March 31, 2024 | 2,033 | 77 | 1 | ₹ |
| Dec. 31, 2023 | 2,053 | 289 | 221 | ₹ |
| Sept. 30, 2023 | 2,034 | 225 | 136 | ₹ |
| June 30, 2023 | 1,588 | 252 | 164 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 9,646 | 1,573 | 1,184 |
| March 31, 2025 | 8,940 | 1,131 | 785 |
| March 31, 2024 | 7,705 | 843 | 523 |
| March 31, 2023 | 6,244 | 745 | 479 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,142 | -247 | -754 | 652 | 490 |
| March 31, 2025 | 1,321 | -870 | -283 | 776 | 546 |
| March 31, 2024 | 945 | -1,292 | -553 | 411 | 533 |
| March 31, 2023 | 806 | -725 | 507 | 494 | 311 |
| March 31, 2022 | 856 | -855 | 427 | 479 | 377 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 12,370 | 9,524 | 8,038 | 595 | 109 | 6,374 | 2,307 | 437 | 4,441 | 2,731 |
| March 31, 2025 | 11,761 | 8,388 | 6,923 | 758 | 543 | 5,967 | 2,384 | 167 | 4,069 | 2,560 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
